[HTML][HTML] Metastatic breast cancer subtypes and central nervous system metastases

C Aversa, V Rossi, E Geuna, R Martinello, A Milani… - The Breast, 2014 - Elsevier
C Aversa, V Rossi, E Geuna, R Martinello, A Milani, S Redana, G Valabrega, M Aglietta…
The Breast, 2014Elsevier
Background Breast cancer (BC) subtypes have different survival and response to therapy.
We studied predictors of central nervous system metastases (CNS-M) and outcome after
CNS-M diagnosis according to tumor subtype. Patients and methods 488 patients with
diagnosis of metastatic BC were retrospectively evaluated. According to the combination of
hormone receptors (HR) and HER2 status, tumors were grouped in: Luminal (Lum),
Luminal/HER2+, pure HER2-positive (pHER2+) and triple negative (TN). Time to CNS …
Background
Breast cancer (BC) subtypes have different survival and response to therapy. We studied predictors of central nervous system metastases (CNS-M) and outcome after CNS-M diagnosis according to tumor subtype.
Patients and methods
488 patients with diagnosis of metastatic BC were retrospectively evaluated. According to the combination of hormone receptors (HR) and HER2 status, tumors were grouped in: Luminal (Lum), Luminal/HER2+, pure HER2-positive (pHER2+) and triple negative (TN). Time to CNS progression, CNS-M free interval and Overall Survival (OS) after CNS-M occurrence were compared by the log-rank test. Cox-proportional hazard models were used to study predictor factors associated with CNS progression, including tumor subtype and all potentially clinical relevant variables.
Results
115 patients (pts) developed CNS-M with a median time to CNS progression of 31 months. The rate of CNS-M by subtype was: Lum 14%, Lum/HER2+ 35%, pHER2+ 49%, TN 22% (p < 0.001). Compared with Lum tumors, Lum/HER2+ (HR 2.514, p < 0.001), pHER2+ (HR 6.799, p < 0.0001) and TN (HR = 3.179, p < 0.001) subtypes were at higher risk of CNS-M. Median OS in months after CNS-M was: Lum 7.4, Lum/HER2+ 19.2, pHER2+ 7, TN 4.9 (p < 0.002). Belonging to the Lum/HER2+ subtype (HR 0.48, p < 0.037) and having isolated CNS (HR 0.37, p < 0.004) predicted significantly reduced risk of death.
Conclusions
After CNS-M, the Lum/HER2+ subtype appears associated with the longest OS. Prospective clinical trials would be required for evaluating the potential role of screening for asymptomatic CNS lesions and of more aggressive CNS-M treatment in Lum/HER2+ subtype.
Elsevier